Drugs / HCP1004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06595004 | Nov 2024 → Jun 2025 | chronic pain syndrome | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Hanmi Pharmaceutical Company Limited | Regulatory 한미 NSAIDs+PPI 복합제 ‘낙소졸’ , 국내 최초 요통 적응증 획득 hanmi.co.kr ↗
한미약품의 진통·소염 복합제 낙소졸(Naproxen/Esomeprazole)이 식품의약품안전처(이하, 식약처)로부터 요통 치료에 대한 적응증을 추가 승인받았다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Hanmi Pharmaceutical Company Limited | 한미 NSAIDs+PPI 복합제 ‘낙소졸’ , 국내 최초 요통 적응증 획득 hanmi.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06595004 ↗ |
| Route | Oral | “Take HCP1004 twice daily for 12 weeks orally.” NCT06595004 ↗ |